Last reviewed · How we verify
Crohn's disease
Approved treatments
- Stelara · Biocon Biologics UK Ltd
Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases. - tumor necrosis factor inhibitors (TNFi) · Pfizer
- Solu-Cortef · Pfizer
- Imuran · Legacy Pharma
- Entyvio · Takeda
Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue. - Abrilada · AbbVie
Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - Cortifoam · Pfizer
- Cortone
- Verdeso · Padagis Us
- Tysabri · Biogen Idec
Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease. - Celestone Soluspan
- Decadron · Generic (originally Merck)
- Humira · AbbVie
Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors. - TNF Inhibitor · Pfizer
- Stelara · Johnson & Johnson
Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation. - Pulmicort Respules · AstraZeneca K.K.
- Cimzia · UCB
Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity. - Remicade · Johnson & Johnson
Infliximab binds to TNFα, blocking its interaction with receptors, reducing inflammation and immune responses. - Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd.
- prednison · Wen Zhang
- Remicade · Johnson & Johnson
Infliximab-dyyb neutralizes TNFα by binding with high affinity to soluble and transmembrane forms, inhibiting receptor binding. - CYLTEZO · BOEHRINGER INGELHEIM
- IXIFI · PFIZER INC
- Medrol · Generic (originally Upjohn/Pfizer)
Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions. - Cortef · Generic (originally Merck/Upjohn)
- Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Rodinolone
- Deltasone · Generic (originally Schering)
- Infliximab [infliximab biosimilar 3] · Pfizer
Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions. - Skyrizi · AbbVie
Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response. - Remicade · Johnson & Johnson
Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage. - Betametasone
Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- Cimzia · University of Washington
- Tysabri · University of Chicago
- prednisolon · Hannover Medical School
- Humira · Sohag University
- Methylprednisolon · Leiden University Medical Center
Clinical guidelines
- FDA label — 1L|2L
Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. - FDA label — 2L
reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. - FDA label — 2L
reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. - FDA label — 2L
reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. - FDA label — 1L|2L
Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Crohn's disease treatment landscape brief
- Crohn's disease treatment updates RSS
Frequently asked questions about Crohn's disease
What drugs treat Crohn's disease?
Tracked treatments include Stelara, tumor necrosis factor inhibitors (TNFi), Solu-Cortef, Imuran, Entyvio, Abrilada, Cortifoam, Cortone.
What is the treatment for Crohn's disease?
Standard treatment for Crohn's disease includes Stelara, tumor necrosis factor inhibitors (TNFi), Solu-Cortef, Imuran, Entyvio. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Crohn's disease?
FDA label publishes guidelines for Crohn's disease. 5 guideline references tracked.
Related
- Treatment landscape: Crohn's disease patent cliff · Crohn's disease CI report
- Treatment: Stelara · Biocon Biologics UK Ltd
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: Solu-Cortef · Pfizer
- Treatment: Imuran · Legacy Pharma
- Treatment: Entyvio · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing